Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

MLA

M.R. Garcia Campelo, et al. “Brigatinib vs Crizotinib in Patients with ALK Inhibitor-Naive Advanced ALK+ NSCLC: Updated Results from the Phase III ALTA-1L Trial.” Annals of Oncology, vol. 30, Nov. 2019, pp. ix195-ix196. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fd540aabf25c4c1717fc7e14fbe56660&authtype=sso&custid=ns315887.

APA

M.R. Garcia Campelo, K.H. Lee, M. Tiseo, Angelo Delmonte, Myung-Ju Ahn, Enriqueta Felip, Maximilian Hochmair, Frank Griesinger, R. Camidge, Sanjay Popat, J-Y. Han, Dai Woo Kim, Pingkuan Zhang, Scott N. Gettinger, J.C.-H. Yang, Raffaele Califano, Q. Ni, Alexander I. Spira, & H.R. Kim. (2019). Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology, 30, ix195-ix196.

Chicago

M.R. Garcia Campelo, K.H. Lee, M. Tiseo, Angelo Delmonte, Myung-Ju Ahn, Enriqueta Felip, Maximilian Hochmair, et al. 2019. “Brigatinib vs Crizotinib in Patients with ALK Inhibitor-Naive Advanced ALK+ NSCLC: Updated Results from the Phase III ALTA-1L Trial.” Annals of Oncology 30 (November): ix195-ix196. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fd540aabf25c4c1717fc7e14fbe56660&authtype=sso&custid=ns315887.